BOSTON, November 13, 2025 — Leads & Copy — Tiziana Life Sciences, Ltd. (Nasdaq: TLSA), a biotechnology company focused on immunomodulation therapies, will present at the Jefferies London Healthcare Conference, showcasing its innovative pipeline and clinical milestones, the company announced today.
The conference, a premier European investor forum, will host Tiziana’s Chief Executive Officer Ivor Elrifi and Chief Operating Officer/Chief Financial Officer Keeren Shah, who will provide a corporate overview and an update on foralumab, Tiziana’s lead candidate. Foralumab is the only fully human anti-CD3 monoclonal antibody in clinical development that is administered intranasally for neurodegenerative diseases. The company will provide updates on foralumab’s potential in treating non-active secondary progressive multiple sclerosis (SPMS), Alzheimer’s disease (AD), multiple system atrophy (MSA) and amyotrophic lateral sclerosis (ALS).
The Jefferies London Healthcare Conference attracts global healthcare companies, institutional investors, and industry thought leaders, offering Tiziana Life Sciences an opportunity to highlight its progress and commitment to transformative therapies.
Foralumab, a fully human anti-CD3 monoclonal antibody, has demonstrated the ability to stimulate T regulatory cells when administered intranasally. An open-label Expanded Access Program (NCT06802328) involving 14 patients with Non-Active Secondary Progressive Multiple Sclerosis (na-SPMS) showed either improvement or stabilization of the disease within six months for all participants. Additionally, intranasal foralumab is currently under evaluation in a Phase 2a, randomized, double-blind, placebo-controlled, multicenter, dose-ranging trial (NCT06292923) for patients with non-active secondary progressive multiple sclerosis.
Tiziana Life Sciences is a clinical-stage biopharmaceutical company developing therapies using drug delivery technologies to enable alternative routes of immunotherapy. The company’s nasal approach aims to improve efficacy, safety, and tolerability compared to intravenous (IV) delivery. Tiziana holds patents for its technology and expects broad applications across its pipeline.
Presentation Details:
- Event: Jefferies London Healthcare Conference
- Date: Wednesday, November 19, 2025
- Time: 12:30 p.m. – 12:55 p.m. GMT (25-minute presentation)
- Location: London, UK
- Presenters:
- Ivor Elrifi, Chief Executive Officer
- Keeren Shah, Chief Operating Officer and Chief Financial Officer
Management will be available for one-on-one meetings throughout the conference. Interested parties may request meetings through the Jefferies conference portal or by contacting Tiziana’s investor relations team.
Paul Spencer, Business Development, and Investor Relations, +44 (0) 207 495 2379, email: info@tizianalifesciences.com
Source: Tiziana Life Sciences
